2 Information about abemaciclib

Marketing authorisation indication

2.1 Abemaciclib (Verzenios, Eli Lilly) 'in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. In pre- or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for abemaciclib.


2.3 The list price for abemaciclib is £2,950 per 28‑day cycle of 150‑mg tablets (£1,475 per 28‑tablet pack or £2,950 per 56‑tablet pack; excluding VAT; BNF online, accessed May 2022).

2.4 The company has a commercial arrangement. This makes abemaciclib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)